T: +91 124 4708 700 |  E: [email protected]    

         

Search

         

         

Search

         

         

Court assesses lung cancer drug patent infringement by the company.

October 18, 2023 by Dr Jyoti Choithani Ramani General, IP, Patent, Pharma & Chemistry
Home | General | Court assesses lung cancer drug patent infringement by the company.

In Chugai Seiyaku Kabushiki Kaisha and Hoffmann-La Roche AG v Frensenius Kabi Oncology Limited and Fresensius Kabi India Private Limited, the plaintiff, Chugair Seiyaku Kabushiki Kaisha (CSKK) sought a permanent injunction against Fresenius Kabi Oncology Limited (FKOL) and Fresensius Kabi India Private Limited for infringing its Indian patent protecting Alectinib, an oral drug used to treat a certain type of non-small-cell lung cancer.

CSKK and its exclusive licencee, Hoffmann-La Roche, contended that, in May 2021, FKOL imported Alectinib and exported Alectinib hydrochloride. CSKK further contended that an independent online investigation revealed various online listings of FKOL for a generic version of Alectinib on the Pharma Compass and Chemical Book websites.


Read More

Stay Ahead with IP Insights That Matter

DISCLAIMER

As per the rules of the Bar Council of India, we are not permitted to solicit work and advertise. By clicking on the “I AGREE” button below, you acknowledge the following:

  • There has been no advertisement, personal communication, solicitation, invitation or inducement of any sort whatsoever from us or any of our members to solicit any work through this website;
  • The user wishes to gain more information about us for his/her own information and use;
  • The information about us is provided to the user only on his/her specific request and any information obtained or materials downloaded from this website is completely at the user’s volition and any transmission, receipt or use of this site would not create any lawyer-client relationship.

The information provided under this website is solely available at your request for informational purposes only, should not be interpreted as soliciting or advertisement. We are not liable for any consequence of any action taken by the user relying on material / information provided under this website. In cases where the user has any legal issues, he/she in all cases must seek independent legal advice.